

Supplementary Table 1: Demographic, clinical and metabolic characteristics at baseline

	Placebo	Rosiglitazone/Metformin	
	(n=104)	(n=103)	P
Age (yrs)	55.0 [46.0-61.0]	50.0 [44.0-61.0]	0.1653
Female	71 (68.3)	67 (65.0)	0.6231
Ethnicity:			0.9729
Caucasian	77 (74.0)	77 (74.8)	
South Asian	7 (6.8)	8 (7.8)	
Latino	7 (6.7)	7 (6.8)	
Others	13 (12.5)	11 (10.7)	
Family history of DM	75 (72.8)	73 (73.0)	0.9764
BMI (kg/m ²)	32.0 [28.3-36.8]	31.3 [27.1-35.7]	0.5649
Waist circumference (cm)	103.0 [94.6-116.4]	104.3 [93.5-113.6]	0.6958
Smoking:			0.5364
Never	63 (60.6)	62 (60.2)	
Remote	31 (29.8)	35 (34.0)	
Current	10 (9.6)	6 (5.8)	
Lipids:			
Total cholesterol (mmol/L)	5.40 [4.80-6.10]	4.90 [4.20-5.60]	0.0002
LDL cholesterol (mmol/L)	3.40 [2.90-4.00]	2.90 [2.30-3.60]	0.0003
HDL cholesterol (mmol/L)	1.10 [1.00-1.40]	1.10 [0.90-1.30]	0.2832
Triglycerides (mmol/L)	1.66 [1.16-2.22]	1.70 [1.17-2.21]	0.9200
IS _{OGTT}	3.0 [2.2-5.5]	2.9 [1.9-4.5]	0.2922

SUPPLEMENTARY DATA

ISSI-2	490 [384-564]	499 [408-603]	0.4095
Oral glucose tolerance test:			
Fasting glucose (mmol/L)	5.4 [5.0-5.9]	5.4 [5.0-5.8]	0.8544
30-mins glucose(mmol/L)	9.8 [8.9-10.8]	9.2 [8.3-10.4]	0.0572
2-hour glucose (mmol/L)	8.8 [8.2-9.9]	8.9 [8.2-9.8]	0.9435
Glucose tolerance status:			0.3149
Isolated IGT	88 (84.6)	92 (89.3)	
Combined IGTand IFG	16 (15.4)	11 (10.7)	

Categorical data are presented as n(%) and continuous variables are presented as median followed by interquartile range.

p-values for continuous variables were obtained by wilcoxon rank-sum test.

p-values for categorical variables were obtained by chi-squared test or fisher's exact test, where necessary.